ClinicalPath (formerly Via Oncology) Publications

Adelson K, et al. Effects of rising drug costs on efforts to control overall cost at a large academic cancer center.
[Abstract] J Clin Oncol 37, 2019 (suppl 27; abstr 2)

Pracilio Csik V et al. Pathways Impact on OCM Drug Cost.
[Abstract] [Poster] J Clin Oncol 37, 2019 (suppl 27; abstr 109)

Rodríguez-Lopéz JL, Ling DC, Heron DE, Beriwal S. Lag Time Between Evidence and Guidelines: Can Clinical Pathways Bridge the Gap?
[Article] JOP. December 2018:JOP.18.00430

Mason C et al. Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting.
[Manuscript] J Clin Pathways 2017 4(1):49-54

Page R et al. Expanding indications of existing drugs and associated costs under risk reimbursement models.
[Abstract] J Clin Oncol 35, 2017 (suppl; abstr e18306)

Ellis PG et al. Using clinical pathways to understand biomarker testing patterns.
[Abstract] J Clin Oncol 35, 2017 (suppl; abstr e18189)

Cost and survival analysis before and after implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer.
[Article] J Oncol Pract. 2017 Apr;13(4):e346-e352

Ellis PG, O’Neil BH, Earle MF, et al. Clinical pathways: management of quality and cost in oncology networks in the metastatic colorectal cancer setting.
[Article] J Oncol Pract. 2017 Apr 5.

Ellis PG et al. Developing and piloting an electronic telephone triage application.
[Abstract] [Poster] J Clin Oncol 35, 2017 (suppl 8S; abstract 137)

Gebhardt BJ et al. Peer review process for implementation of clinical pathways (CP): Does it improve compliance?
[Abstract] Pract Radiat Oncol. 2017 Jan 19. pii: S1879-8500(17)30006-1. doi: 10.1016/j.prro.2017.01.006.